REPRISE III Completes Enrollment

First US Head-to-Head Lotus Valve vs. CoreValve Study Update

REPRISE III PI’s Dr. Feldman and Dr. Reardon Share Insight on Recent and Upcoming Milestones for the Lotus Valve

Dr. Ted Feldman
Dr. Michael Reardon
“We are pleased to report that as of December 2015, 1014 patients have enrolled in REPRISE III which completes enrollment in the trial. REPRISE III is exciting as this is the first head-to-head device vs device randomized controlled trial for TAVR in the US. Our gratitude goes out to all sites for their dedication to the Lotus Valve clinical program. We would also like to extend a special thanks to the top 3 enrolling centers in the US: Piedmont, Cedars-Sinai, and Houston Methodist. In addition to the completion of the REPRISE III trial enrollment, the European registry RESPOND has also completed enrollment this month with 1004 patients. 2016 will be an important year for the Lotus Valve as we anticipate having an expanded size matrix, the completion of enrollment for REPRISE Japan, and the start of the continued access study.”

View Recent Lotus Valve Clinical Data Presentations

Lotus Valve System
Review the REPRISE III Study Design
REPRISE III Study Design
Top